Contact this trialFirst, we need to learn more about you.
Virus Vaccine
Recombinant vs Egg-Based Flu Vaccine for Adults
Recruiting3 awardsPhase 4
Tucson, Arizona
This trial will compare the clinical efficacy of a new recombinant influenza vaccine to a standard egg-based influenza vaccine among adults aged 18-64 years. The primary hypothesis is that the new vaccine is superior to the standard vaccine in preventing and attenuating influenza-like illness. Relative efficacy and immunogenicity will be assessed by comparing rates of influenza virus infection and measures of infection and illness attenuation among participants who receive the new vaccine versus the standard vaccine.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.